FDA
-
-
-
-
-
-
-
AMGEN presents data on rare disease drugs at european medical congress
-
-
-
-
-
-
-
AstraZeneca, Amgen partner with FDA to test real-time AI trial monitoring
-
-
-
-
-
-
-
FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
-
-
-
-
-
-
-
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
-
-
-
-
-
-
-
AMGEN to present Repatha trial data at heart association meeting
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
FDA expands AMGEN's Repatha approval for cardiovascular risk reduction
-
329,502 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

